Your browser doesn't support javascript.
loading
The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts.
Zhong, Yan; Deng, Lin; Shi, Shuo; Huang, Qiu-Yao; Ou-Yang, Shu-Min; Mo, Jian-Shan; Zhu, Kai; Qu, Xin-Ming; Liu, Pei-Qing; Wang, Yuan-Xiang; Zhang, Xiao-Lei.
Afiliação
  • Zhong Y; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Deng L; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Shi S; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Huang QY; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Ou-Yang SM; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Mo JS; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Zhu K; Innovation Practice Center, Changchun University of Chinese Medicine, Changchun, 130117, China.
  • Qu XM; Innovation Practice Center, Changchun University of Chinese Medicine, Changchun, 130117, China.
  • Liu PQ; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Wang YX; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
  • Zhang XL; National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Engineering Laboratory of Druggability and New Drug Evaluation, Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006,
Acta Pharmacol Sin ; 43(4): 1013-1023, 2022 Apr.
Article em En | MEDLINE | ID: mdl-34267347
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias de Mama Triplo Negativas Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Acta Pharmacol Sin Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias de Mama Triplo Negativas Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Acta Pharmacol Sin Ano de publicação: 2022 Tipo de documento: Article